Molecular Partners Announces Research Collaboration with University of Bern to Develop MP0533, a Multispecific DARPin for the Treatment of AML

Molecular Partners AG announced a research collaboration with University of Bern, to advance the development of the company’s wholly owned acute myeloid leukemia candidate, MP0533, into the clinic.